Determination of the therapeutic effect of the intravitreal administration of autologous adipose derived-mesenchymal stromal cells combined with anti-VEGF nanocarriers, in an animal model of induced retinal vein occlusion

Purpose: This work aims to investigate real-world treatment patterns and outcomes in eyes with branch retinal vein occlusion in the antivascular endothelial growth factor (anti-VEGF) era. Methods: A retrospective, nonrandomized, comparative study was conducted on eyes diagnosed with branch retinal vein occlusion at a single tertiary center between 2009 and 2017. Medical history, treatment patterns, and visual acuity outcomes were examined. Subanalysis was performed for eyes that met the eligibility criteria for the BRAVO (Ranibizumab for the Treatment of Macular Edema Following Branch Retinal Vein Occlusion) trial. Results: A total of 315 eyes were included, of which 244 were treatment naive. In all eyes, the most common first treatment was the following: intravitreal bevacizumab (38.4%), aflibercept (15.1%), ranibizumab (8.1%), sectoral scatter laser (6.2%), and triamcinolone (3.1%). At 1 year, treatment-naive eyes had received an average of 2.43 anti-VEGF injections. During follow-up, treatment-naive eyes gained an average of 0.21 Early Treatment Diabetic Retinopathy Study lines. Forty eyes that met BRAVO trial criteria received an average of 5.05 anti-VEGF injections in the first year and gained an average of 1.83 Early Treatment Diabetic Retinopathy Study lines. Conclusions: This real-world cohort received fewer anti-VEGF injections at year 1 and experienced less improvement in visual acuity during the course of treatment than clinical trial participants. Trial-eligible patients received more injections and had greater visual gains than those who would not have been eligible for the trial.

Download Full-text

Retinal venous pressure is decreased after anti-VEGF therapy in patients with retinal vein occlusion–related macular edema

Graefe s Archive for Clinical and Experimental Ophthalmology ◽

10.1007/s00417-020-05068-x ◽

2021 ◽

Author(s):

Teruyo Kida ◽

Josef Flammer ◽

Katarzyna Konieczka ◽

Tsunehiko Ikeda

Keyword(s):

Macular Edema ◽

Intravitreal Injection ◽

Retinal Vein Occlusion ◽

Venous Pressure ◽

Decisive Role ◽

Retinal Venous Pressure ◽

Vein Occlusion ◽

Anti Vegf ◽

Significant Difference ◽

Endothelial Growth Factor

Abstract Purpose The pathomechanism leading to retinal vein occlusion (RVO) is unclear. Mechanical compression, thrombosis, and functional contractions of veins are discussed as the reasons for the increased resistance of venous outflow. We evaluated changes in the retinal venous pressure (RVP) following intravitreal injection of anti-vascular endothelial growth factor (VEGF) agent to determine the effect on RVO-related macular edema. Methods Twenty-six patients with RVO-related macular edema (16 branch RVOs [BRVOs] and 10 central RVOs [CRVOs], age 72.5 ± 8.8 years) who visited our hospital were included in this prospective study. Visual acuity (VA), intraocular pressure (IOP), central retinal thickness (CRT) determined by macular optical coherence tomography, and RVP measured using an ophthalmodynamometer were obtained before intravitreal injection of ranibizumab (IVR) and 1 month later. Results Comparison of the BRVOs and CRVOs showed that VA was significantly improved by a single injection in BRVOs (P < 0.0001; P = 0.1087 for CRVOs), but CRT and RVP were significantly decreased without significant difference in IOP after the treatment in both groups (P < 0.0001). Conclusion The anti-VEGF treatment resulted in a significant decrease in the RVP, but the RVP remained significantly higher than the IOP. An increased RVP plays a decisive role in the formation of macula edema, and reducing it is desirable.

Download Full-text

A tissue engineering construct comprising human endometrial mesenchymal stromal cells and polyamide/gelatin mesh evaluated in a preclinical animal model of pelvic organ prolapse repair

Cytotherapy ◽

10.1016/j.jcyt.2013.01.016 ◽

2013 ◽

Vol 15 (4) ◽

pp. S5

Author(s):

D. Ulrich ◽

S.L. Edwards ◽

J.F. White ◽

C. Su ◽

K. Tan ◽

...

Keyword(s):

Tissue Engineering ◽

Animal Model ◽

Pelvic Organ Prolapse ◽

Mesenchymal Stromal Cells ◽

Stromal Cells ◽

Pelvic Organ ◽

Prolapse Repair ◽

Preclinical Animal Model ◽

Tissue Engineering Construct ◽

Pelvic Organ Prolapse Repair

Download Full-text

Determination of the membrane hydraulic permeability of MSCs

Current Directions in Biomedical Engineering ◽

10.1515/cdbme-2016-0072 ◽

2016 ◽

Vol 2 (1) ◽

pp. 323-327

Author(s):

Jennifer Contreras Lopez ◽

Lothar Lauterböck ◽

Birgit Glasmacher

Keyword(s):

Activation Energy ◽

Bone Marrow ◽

Cooling Rate ◽

Mesenchymal Stromal Cells ◽

Stromal Cells ◽

Hydraulic Permeability ◽

Osmotic Behaviour ◽

Additional Influence ◽

Dimethyl Sulfoxid

AbstractA successful cryopreservation is based on knowledge of the optimal cooling rate. So far, this is often determined by way of complex parameter studies. Alternatively, the identification of cell specific characteristics, such as osmotic behaviour, membrane hydraulic permeability and activation energy could be used to calculate the optimal cooling rate. These parameters should be determined for supra-zero and sub-zero temperatures. In this study cryomicroscopy was used. Mesenchymal stromal cells (MSCs) from bone marrow were analysed. The determined membrane hydraulic permeability for sub-zero temperatures is significantly lower than that for supra-zero temperatures. On the contrary the activation energy is significantly higher in the presence of ice. The addition of a cryoprotective agent (CPA) such as dimethyl sulfoxid (DMSO) shows an additional influence on the characteristics of the membrane of the cell. The optimal cooling rate was determined with these parameters. For cryopreservation without DMSO the optimal cooling rate was found to be 12.82 K/min. If the MSCs were frozen with 5% (v/v) DMSO the optimal cooling rate is 16.25 K/min.

Download Full-text

The Effect of Antivascular Endothelial Growth Factor Therapy on the Development of Neovascular Glaucoma after Central Retinal Vein Occlusion: A Retrospective Analysis

Journal of Ophthalmology ◽

10.1155/2014/317694 ◽

2014 ◽

Vol 2014 ◽

pp. 1-6 ◽

Cited By ~ 3

Author(s):

Christina L. Ryu ◽

Adrian Elfersy ◽

Uday Desai ◽

Thomas Hessburg ◽

Paul Edwards ◽

...

Keyword(s):

Macular Edema ◽

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Significant Risk ◽

Case Series ◽

Neovascular Glaucoma ◽

Vein Occlusion ◽

Anti Vegf ◽

Central Retinal Vein

Purpose. Ischemic central retinal vein occlusion (CRVO) eyes are at high risk of developing neovascular glaucoma (NVG). Our purpose is to investigate the effect of anti-VEGF therapy for macular edema after CRVO on the development of neovascular glaucoma (NVG) in ischemic CRVO eyes.Methods. This is a retrospective case series of 44 eyes from 44 patients with CRVO treated with anti-VEGF therapy for macular edema. The primary outcome was the development of NVG.Results. Of the 44 eyes, 14 eyes had ischemic CRVO, and 30 eyes had nonischemic CRVO. Nonischemic eyes received a mean of 8.4 anti-VEGF doses, over mean follow-up of 24 months. One nonischemic eye (3.3%) developed NVD but not NVG. The 14 ischemic eyes received a mean of 5.6 anti-VEGF doses, with mean follow-up of 23 months. Of these 14 ischemic eyes, two eyes (14%) developed iris neovascularization and 3 eyes (21%) developed posterior neovascularization. Three of these 5 eyes with neovascularization progressed to NVG, at 19.7 months after symptom onset, on average.Conclusion. Anti-VEGF therapy for macular edema may delay, but does not prevent, the development of ocular NV in ischemic CRVO. Significant risk of NVG still exists for ischemic CRVO eyes.

Download Full-text

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)

Clinical Ophthalmology ◽

10.2147/opth.s163859 ◽

2018 ◽

Vol Volume 12 ◽

pp. 621-629 ◽

Cited By ~ 12

Author(s):

J Michael Jumper ◽

Pravin Dugel ◽

Sanford Chen ◽

Kevin Blinder ◽

John Walt

Keyword(s):

Clinical Practice ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Study Report ◽

Vein Occlusion ◽

Anti Vegf ◽

Patterns Of Use

Download Full-text

Loss to Follow-Up in Patients With Retinal Vein Occlusion Undergoing Intravitreal Anti-VEGF Injections

Ophthalmic Surgery Lasers and Imaging Retina ◽

10.3928/23258160-20190301-05 ◽

2019 ◽

Vol 50 (3) ◽

pp. 159-166 ◽

Cited By ~ 1

Author(s):

Xinxiao Gao ◽

Anthony Obeid ◽

Murtaza K. Adam ◽

Leslie Hyman ◽

Allen C. Ho ◽

...

Keyword(s):

Retinal Vein Occlusion ◽

Loss To Follow Up ◽

Vein Occlusion ◽

Anti Vegf

Download Full-text

Initial treatment of macular oedema due to central retinal vein occlusion—which anti-VEGF agent to choose?

Eye ◽

10.1038/s41433-019-0706-6 ◽

2019 ◽

Vol 34 (2) ◽

pp. 219-220

Author(s):

Elad Moisseiev ◽

Anat Loewenstein

Keyword(s):

Retinal Vein Occlusion ◽

Central Retinal Vein Occlusion ◽

Macular Oedema ◽

Initial Treatment ◽

Vein Occlusion ◽

Anti Vegf ◽

Central Retinal Vein

Download Full-text

Comparison of intravitreal dexamethasone implant and anti-VEGF drugs in the treatment of retinal vein occlusion-induced oedema: a meta-analysis and systematic review

BMJ Open ◽

10.1136/bmjopen-2019-032128 ◽

2020 ◽

Vol 10 (6) ◽

pp. e032128

Author(s):

Shuai Ming ◽

Kunpeng Xie ◽

Mingzhu Yang ◽

Huijuan He ◽

Ya Li ◽

...

Keyword(s):

Systematic Review ◽

Retinal Vein Occlusion ◽

Real World ◽

Meta Analysis ◽

Real Life ◽

Cochrane Library ◽

Efficacy And Safety ◽

Vein Occlusion ◽

Anti Vegf ◽

Intravitreal Dexamethasone

ObjectiveTo compare the efficacy and safety of intravitreal dexamethasone (DEX) implant and anti-vascular endothelial growth factor (anti-VEGF) agents in the treatment of macular oedema secondary to retinal vein occlusion (RVO).DesignSystematic review and meta-analysis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE).Data sourcesPubMed, Cochrane Library and ClinicalTrials.gov registry were searched from inception to 10 December 2019, without language restrictions.Eligibility criteriaRandomised controlled trials (RCTs) and real-world observation studies comparing the efficacy of DEX implant and anti-VEGF agents for the treatment of patients with RVO, naïve or almost naïve to both arms, were included.Data extraction and synthesisTwo reviewers independently extracted data for mean changes in best-corrected visual acuity (BCVA), central subfield thickness (CST) and product safety. Review Manager V.5.3 and GRADE were used to synthesise the data and validate the evidence, respectively.ResultsFour RCTs and 12 real-world studies were included. An average lower letter gain in BCVA was determined for the DEX implant (mean difference (MD) = −6.59; 95% CI −8.87 to −4.22 letters) administered at a retreatment interval of 5–6 months. Results were similar (MD6 months=−12.68; 95% CI −21.98 to −3.37 letters; MD12 months=−9.69; 95% CI −12.01 to −7.37 letters) at 6 and 12 months. The DEX implant resulted in comparable or marginally less CST reduction at months 6 and 12 but introduced relatively higher risks of elevated intraocular pressure (RR=3.89; 95% CI 2.16 to 7.03) and cataract induction (RR=5.22; 95% CI 1.67 to 16.29). Most real-life studies reported an insignificant numerical gain in letters for anti-VEGF drugs relative to that for DEX implant. However, the latter achieved comparable efficacy with a 4-month dosage interval.ConclusionCompared with anti-VEGF agents, DEX implant required fewer injections but had inferior functional efficacy and safety. Real-life trials supplemented the efficacy data for DEX implant.

Download Full-text